secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001753926-24-000474
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical appoints Daniel Bradbury to Board; former Amylin CEO led first once-weekly GLP-1 drug
--------------------------------------------------------------------------------

- Daniel Bradbury appointed to board effective March 4, 2024, filling newly created vacancy expanding board from 5 to 6 members.
- Bradbury was CEO of Amylin Pharmaceuticals until its $7.1B acquisition by Bristol-Myers Squibb in 2012; Amylin secured first once-weekly GLP-1 approval (Bydureon).
- He will serve on Audit Committee; annual retainers: $35,000 for board, $10,000 for committee.
- His GLP-1 expertise aligns with Vivani's lead programs: six-month GLP-1 implants NPM-115 (obesity) and NPM-119 (type 2 diabetes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/0001753926-24-000474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/g084105_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer